Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Malaysia ETF (EWM) vs Cassava Sciences Inc (FLNA) Price & Performance

iShares MSCI Malaysia ETFTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Malaysia ETF vs Cassava Sciences Inc — how do they compare? iShares MSCI Malaysia ETF trades at $27.97, while Cassava Sciences Inc trades at $1.1 (market cap $53.14M). The key difference: iShares MSCI Malaysia ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

EWMFLNA
Sector
Broad Market / FactorHealth
52-Week High
$30.42$4.64
52-Week Low
$23.49$1.09
Market Cap
$53.14M
Enterprise Value
-$33.43M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Malaysia ETF

EWM (iShares MSCI Malaysia ETF) trades at $28.005, down 0.3% on the day, with technical indicators showing a bullish bias despite overbought RSI readings. The ETF provides concentrated exposure to Malaysia's financial (54%) and industrial (21%) sectors, benefiting from the country's data center expansion, semiconductor ambitions, and tourism initiatives. Recent news highlights Malaysia's energy diversification efforts amid regional power demand surges.

The outlook remains constructive given Malaysia's structural growth drivers, though investors face currency risk, regional geopolitical tensions, and dependence on global semiconductor demand. Current technical strength suggests near-term upside potential, but elevated RSI levels warrant caution for entry timing.

Cassava Sciences Inc

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

Returns comparison

Trailing returns across standard periods

About iShares MSCI Malaysia ETF

EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.

Read more on EWM

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA